RxDoctor Payments Data

Charles Butrey, MD

Family Medicine · Avon, OHNPI 1013129394

Payments from drug & device makers

$17,011in general payments, 2019–2025

Across 1,128 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • Pfizer$1K
  • GSK$1K
  • AstraZeneca$1K
  • Novartis$996
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$16,90499%
  • Education$1071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)197$3,121
Novo Nordisk141$1,889
Pfizer99$1,335
GSK82$1,093
AstraZeneca62$1,057
Novartis75$996
Amgen(2 entities)52$988
Merck45$677
Johnson & Johnson34$506
Lilly USA, LLC36$504
E.r. Squibb & Sons, L.L.C.24$400
Boehringer Ingelheim26$379
Takeda Pharmaceuticals U.S.A., Inc.28$292
Astellas Pharma US Inc15$272
Lundbeck LLC17$261
Teva Pharmaceuticals USA, Inc.15$225
Exact Sciences9$179
Amarin Pharma, Inc.12$174
Vanda Pharmaceuticals Inc.5$172
Sunovion Pharmaceuticals Inc.10$164
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$157
Bayer9$155
Abbott9$154
Dexcom, Inc.7$151
Ironshore Pharmaceuticals Inc.9$136
Otsuka America Pharmaceutical, Inc.7$131
Biohaven Pharmaceutical Holding Company Ltd.10$129
Biohaven Pharmaceuticals, Inc.9$128
Kowa Pharmaceuticals America, Inc.8$111
Hikma Pharmaceuticals USA7$108
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$102
Axsome Therapeutics, Inc.4$82
Eisai Inc.4$73
Jazz Pharmaceuticals Inc.4$62
Corcept Therapeutics3$61
Nestle Healthcare Nutrition Inc.3$56
Xeris Pharmaceuticals, Inc.3$56
Bausch Health US, LLC4$53
Sumitomo Pharma America, Inc.2$39
Ironwood Pharmaceuticals, Inc2$35
Evoke Pharma, Inc.2$31
Clarus Therapeutics Inc.2$30
Amneal Pharmaceuticals LLC2$25
Vertex1$24
Inspire Medical Systems, Inc.1$20
Scilex Pharmaceuticals Inc.1$19
Supernus Pharmaceuticals, Inc.1$17
Avanir Pharmaceuticals, Inc.1$16
IBSA Pharma Inc.1$15
Eyevance Pharmaceuticals LLC1$15
Azurity Pharmaceuticals, Inc.1$15
Melinta Therapeutics, LLC1$15
Sanofi Pasteur Inc.1$14
Esperion Therapeutics, Inc.1$14
Neos Therapeutics, LP1$14
Sanofi-aventis U.S. LLC1$14
Collegium Pharmaceutical, Inc.1$13
Idorsia Pharmaceuticals US Inc1$13
Vivus LLC1$12
Upsher-smith Laboratories LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,011 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$122,801
Medicare patients
237
Services billed
4,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide298$373,108
JardianceEmpagliflozin237$257,453
FarxigaDapagliflozin Propanediol126$143,320
RybelsusSemaglutide62$124,133
EntrestoSacubitril/Valsartan107$122,943
EliquisApixaban101$111,921
Trelegy ElliptaFluticasone/Umeclidin/Vilanter116$100,980
XareltoRivaroxaban136$94,236
MounjaroTirzepatide80$91,579
JanuviaSitagliptin Phosphate43$58,857
XifaxanRifaximin13$53,101
LinzessLinaclotide67$48,417
MyrbetriqMirabegron31$31,031
VraylarCariprazine Hcl15$22,132
RexultiBrexpiprazole13$19,647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,889$497,241360 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$379$284,679281 claims
AstraZenecaFarxiga, Symbicort$1,057$151,960155 claims
PfizerEliquis, Nurtec Odt$1,335$131,139113 claims
NovartisEntresto$996$122,943107 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,093$111,278138 claims
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$504$109,977116 claims
Johnson & JohnsonXarelto$506$94,236136 claims
AbbVieLinzess, Vraylar$3,121$70,54982 claims
MerckJanuvia$677$58,85743 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$157$53,10113 claims
Astellas Pharma US IncMyrbetriq$272$31,03131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Avon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →